Antibiotic developer Nabriva enters into $75M loan deal

With two potential product launches on the horizon, Nabriva Therapeutics has entered into loan agreement valued at up to $75 million with Hercules Capital. Earlier this week, Nabriva (NASDAQ: NBRV) filed two new drug applications seeking approval for intravenous and oral formulations of Lefamulin to treat community-acquired bacterial pneumonia. Last month the company — which is based in Dublin, Ireland, and has its U.S. headquarters in King of Pru ssia — filed a new drug application for Contepo,…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news